In single-pass perfused rat liver, the sinusoidal uptake ofinfused 3H-labelled leukotriene (LT) C4 (10 nmol . 1-') was inhibited by sulfobromophthalein. Inhibition was half-maximal at sulfobromophthalein concentrations of approximately 1.2 pmol . 1-' in the influent perfusate and leukotriene uptake was inhibited by maximally 34%.Sulfobromophthalein (20 pmol . 1-I) also decreased the uptake of infused [3H]LTE4 (10 nmol . I-') by 31%.Indocyanine green (10 pmol . 1-') inhibited the sinusoidal [3H]LTC4 uptake by 19%.Replacement of sodium in the perfusion medium by choline decreased the uptake of infused [3H]LTC4(10 nmol . 1-') by 56%, but was without effect on the uptake of sulfobromophthalein.The canalicular excretion of LTC4, LTD4 and N-acetyl-LTE, was inhibited by sulfobromophthalein. In contrast, the proportion of polar w-oxidation metabolites recovered in bile following the infusion of [3H]LTC4 was increased. Taurocholate, which had no effect on the sinusoidal leukotriene uptake, increased bile flow and also the biliary elimination of the radioactivity taken up. With increasing taurocholate additions, the amount of LTD, recovered in bile increased at the expense of LTC4.Following the infusion of [3H]LTD4 (10 nmol . 1-I), a major biliary metabolite was LTC4 indicating a reconversion of LTD, to LTC,. In the presence of taurocholate (40 pmol . 1-I), however, this reconversion was completely inhibited.The findings suggest the involvement of different transport systems in the sinusoidal uptake of cysteinyl leukotrienes. LTC4 uptake is not affected by bile acids and has a sodium-dependent and a sodium-independent component, the latter probably being shared with organic dyes. Sulfobromophthalein also interferes with the canalicular transport of LTC4, LTD4 and N-acetyl-LTE4, but not with the excretion of w-oxidized cysteinyl leukotrienes. The data may be relevant for the understanding of hepatic leukotriene processing in conditions like hyperbilirubinemia or cholestasis.The cysteinyl leukotrienes (LT) LTC4, LTD4 and LTE4, potent lipid mediators of inflammation, are effectively eliminated from circulating blood [l]. In a variety of species the liver is the major site of leukotriene uptake [2-51, whereas in ximates both biliary and urinary excretion contribute to the :limination of cysteinyl leukotrienes [6, 71. Hepatic processing of leukotrienes includes extracellular degradation of LTC4 to LTD4 and LTE4 catalyzed by the ectoenzymes y-glutamyltransferase and y-glutamyldipeptidase [S], uptake into the hepatocytes, intracellular metabolism and biliary excretion. In rat livers, LTE4 is intracellularly Nacetylated [9, lo], followed by w-oxidation and subsequent chain shortening by /?-oxidation from the w-carboxyl end [l 1 -131. The biliary compartment most likely also contributes to leukotriene metabolism by interconverting biliary LTC4 and LTD4 due to the high activity of y-glutamyltransferase in the canalicular and bile duct membranes ~4 1 .